Shots: The P-III RATIONALE 309 study involves assessing tislelizumab + gemcitabine + cisplatin vs PBO combined with gemcitabine + cisplatin as a 1L treatment in 263 patients in a ratio […]readmore
Tags : RATIONALE 309